By Sara
Depo-Provera is a hormonal birth control injection linked to an increased risk of meningiomas, a type of brain tumor. Recent research has raised serious concerns, and many long-term users are now asking questions about their health and legal options.
A 2024 study in the British Medical Journal found that prolonged use of Depo-Provera significantly raised meningioma risk compared to non-users. If you or someone you love has been diagnosed with a brain tumor caused by Depo-Provera use, understanding the science and your rights is a critical first step.
Depo-Provera is the brand name for medroxyprogesterone acetate, a synthetic progestin given as an injection every three months. It works by preventing ovulation and has been FDA-approved since 1992. Unlike daily birth control pills, it delivers a sustained high dose of synthetic hormone directly into the bloodstream.
That prolonged hormonal exposure is at the center of growing medical and legal concern.
The 2024 British Medical Journal study found that users who took Depo-Provera for more than one year faced a significantly higher meningioma risk. Researchers described a clear dose-response relationship, meaning risk grew with longer use.
Key findings include:
Long-term users had more than five times the meningioma risk compared to non-users.
The elevated risk was specific to medroxyprogesterone acetate, not all progestin-based contraceptives.
Tumors in Depo-Provera users tended to be larger and more likely to need surgery
Risk remained elevated even after patients stopped using the injection.
A meningioma is a tumor that forms in the meninges, the protective tissue surrounding the brain and spinal cord. Many are classified as benign, but they can still cause serious harm depending on size and location.
Common symptoms include:
Persistent headaches
Vision or hearing changes
Seizures
Memory problems
Weakness or numbness in the limbs
Treatment typically involves surgery, radiation, or both. Recovery can be lengthy, and some patients experience long-term neurological effects even after successful treatment.
This is one of the central questions in ongoing litigation. Critics argue that Pfizer failed to adequately warn patients and doctors about the meningioma risk tied to long-term use.
Drug manufacturers have a legal duty to disclose known risks under federal product liability law. When they fail to do so, injured patients may have grounds for a failure-to-warn lawsuit.
You may have legal options if you used Depo-Provera long-term and were later diagnosed with a meningioma. Eligibility generally depends on duration of use, timing of diagnosis, and whether the lack of warning contributed to your injury.
Courts are currently consolidating many of these claims into coordinated proceedings. That process may affect how and where individual cases are filed, so acting sooner rather than later matters.
Depo-Provera has been linked to a significantly higher risk of meningioma brain tumors in long-term users.
A 2024 British Medical Journal study found users faced more than five times the risk compared to non-users.
Meningiomas can cause serious neurological symptoms and often require surgery or radiation.
Pfizer faces legal claims for allegedly failing to warn patients about this risk.
Long-term users who developed meningiomas may have grounds for a product liability lawsuit.
Consulting a legal professional is an important step if you believe Depo-Provera caused your diagnosis.
MBTpg
